'Golden' Gilles Gagnon: A Model President and CEO:Gilles has never sold a single share of CZO in the decade he's been President and CEO. How many have demonstrated that commitment? He's dedicated the most important years of his professional life to this company after success with Novartis and Sandoz. He has only added shares through option exercise and open market purchases. When he became President and CEO CZO's stock was just $.095. Today it is $.63 despite the worst biotech bear market in history due to multi-decade high inflation. Revenue has compounded at a double digit rate during his decade tenure. The company has successfully moved from a business incubator into its own state-of-the-art facility and to consistent profitability. It's multi-product pipeline is now before key catalysts and is composed of world firsts as CZO reaches an inflection point in its pursuit of becoming a high value life sciences company. Canadian pharma icon Ronnie Miller, from the second largest biotech in the world(Roche), has recently joined the company and become Chairman. Mr. Miller has praised the company. Symrise, a C$20 billion market cap company, has recently signed a new long-term agreement and it has resulted in strong sales to date. Dr. Kjetil Ask, now a leading scientists at Novartis, has expressed his excitement concerning PGX-YBG and fibrosis. Fibrosis is attributed to over 40% of deaths worldwide. PGX-YBG itself is multi-fold more immune stimulatory than competing products making it a potential gold standard in a billion dollar market. It can also be used with alginate as a delivery system as evidenced by recently released bioavailability results. With the only commercial-scale production of natural avenanthramide in the world CZO's pharma-grade avenanthramide pill, recently aproved by Health Canada for human testing, promises to target one of humanity's leading killers, inflammation. It may also help manage diabetes. Just like CZO has made available the ancient benefits of oats to the skin as with Aveeno it now seeks to provide an ancient benefit of oats beneath the skin in the form of a neutraceutical. One of the most respected scientists in the food as nutrician sciences, Dr. William Li, is on board. He is also a leading and published expert on COVID and angiogenesis. Dr. Jean-Claude Tardif is a leading global authority on inflammation and heart disease and will be leading CZO's avenanthramide clinical trial.
"“Given the favorable effects of avenanthramide and the increased knowledge on inflammation-based diseases, especially in the cardiovascular area, we believe this study will offer insights in this first-in-class product for a potential new approach for patients,” commented Dr. Jean-Claude Tardif, Director of the Montreal Heart Institute Research Center and Principal Investigator for this clinical trial."